MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Has Average Price Target of $31.33 According to Brokerages

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) have received a consensus rating of “Moderate Buy” from the fifteen brokerages that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $31.33.

MLTX has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of MoonLake Immunotherapeutics in a report on Monday, October 5th. Weiss Ratings lowered MoonLake Immunotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, November 13th. Wedbush set a $34.00 price objective on MoonLake Immunotherapeutics and gave the company an “outperform” rating in a research note on Thursday, November 12th. Cantor Fitzgerald restated an “overweight” rating on shares of MoonLake Immunotherapeutics in a research note on Wednesday, September 16th. Finally, Wall Street Zen downgraded MoonLake Immunotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, September 27th.

View Our Latest Stock Analysis on MoonLake Immunotherapeutics

MoonLake Immunotherapeutics Stock Performance

Shares of MLTX stock opened at $11.04 on Wednesday. The company has a quick ratio of 9.13, a current ratio of 9.13 and a debt-to-equity ratio of 0.26. The company has a 50-day moving average of $11.61 and a two-hundred day moving average of $16.13. MoonLake Immunotherapeutics has a 1-year low of $9.46 and a 1-year high of $23.29.

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.10). Equities analysts anticipate that MoonLake Immunotherapeutics will post -3.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of large investors have recently modified their holdings of the business. Algert Global LLC boosted its holdings in MoonLake Immunotherapeutics by 96.9% during the third quarter. Algert Global LLC now owns 762,031 shares of the company’s stock worth $8,916,000 after buying an additional 375,071 shares in the last quarter. Quarry LP increased its holdings in MoonLake Immunotherapeutics by 8,400.0% in the third quarter. Quarry LP now owns 10,200 shares of the company’s stock valued at $119,000 after buying an additional 10,080 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in MoonLake Immunotherapeutics by 447.7% in the third quarter. Goldman Sachs Group Inc. now owns 708,942 shares of the company’s stock valued at $8,295,000 after buying an additional 579,508 shares in the last quarter. Entropy Technologies LP grew its holdings in MoonLake Immunotherapeutics by 497.4% in the third quarter. Entropy Technologies LP now owns 118,445 shares of the company’s stock valued at $1,386,000 after purchasing an additional 98,618 shares during the last quarter. Finally, Jump Financial LLC lifted its stake in MoonLake Immunotherapeutics by 74.2% in the 3rd quarter. Jump Financial LLC now owns 585,703 shares of the company’s stock valued at $6,853,000 after buying an additional 249,460 shares in the last quarter. 93.85% of the stock is owned by hedge funds and other institutional investors.

MoonLake Immunotherapeutics Company Profile

(Get Free Report)

MoonLake Immunotherapeutics is a Switzerland-based clinical-stage biopharmaceutical company focused on developing treatments for inflammatory skin and joint diseases. The company was established in 2021 and is headquartered in Zug. Its lead investigational medicine, sonelokimab, is a nanobody designed to inhibit the inflammatory proteins IL-17A and IL-17F. MoonLake is studying the drug as a potential treatment for conditions including hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis.

Featured Articles

Analyst Recommendations for MoonLake Immunotherapeutics (NASDAQ:MLTX)

Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.